SCHEMBL2016789

SCHEMBL2016789

c1ccc2c(-c3nnc(-c4cn5c6c(cccc46)CCC5)o3)cccc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
ALOX15 P16050 4/20 0.44
KDM4E B2RXH2 4/20 0.43
RAB9A P51151 4/20 0.43
HSD17B10 Q99714 4/20 0.43
ALDH1A1 P00352 3/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C19 P33261 1/20 0.43
ATM Q13315 1/20 0.43
NPC1 O15118 2/20 0.42
HPGD P15428 2/20 0.42
TSHR P16473 1/20 0.42
BCHE P06276 1/20 0.41
ACHE P22303 1/20 0.41
TDP1 Q9NUW8 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ALOX12 P18054 1/20 0.39
OPA1 O60313 1/20 0.38
EIF5B O60841 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2021179 0.88 RAB9A (0.51) HTR2AHTR2CKDM4ERAB9AHSD17B10
SCHEMBL2024432 0.88 RAB9A (0.51) HTR2AHTR2CKDM4ERAB9AHSD17B10
SCHEMBL2016603 0.87 HTR2A (0.46) HTR2AHTR2CKDM4ERAB9AHSD17B10
SCHEMBL2021453 0.86 RAB9A (0.49) HTR2AHTR2CALOX15KDM4ERAB9A
SCHEMBL2021806 0.85 ALDH1A1 (0.44) HTR2AHTR2CALOX15KDM4ERAB9A
SCHEMBL2018600 0.82 HTR2A (0.46) HTR2AHTR2CHSD17B10ALDH1A1HPGD
SCHEMBL2020405 0.81 NPC1 (0.43) HTR2AHTR2CKDM4ERAB9AHSD17B10
SCHEMBL2015858 0.81 RAB9A (0.48) HTR2AHTR2CKDM4ERAB9AHSD17B10
SCHEMBL2019352 0.81 NPC1 (0.46) HTR2AHTR2CALOX15KDM4ERAB9A
SCHEMBL2020602 0.81 NPC1 (0.44) HTR2AHTR2CALOX15KDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
WO-2011082266-A2 SUBSTITUTED HETEROCYCLIC COMPOUNDS ARQULE, INC. (US) 2011-07-07 WO disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160237-A1 Substituted Heterocyclic Compounds MKI67, CCNC, NQO1 HTR2A 1440/4885HTR2C 632/4885ALOX15 661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.